Study Status: COMPLETED
Recruit Status: COMPLETED
Study Type: INTERVENTIONAL
Official Title: An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of REPLAGAL� in Treatment-na�ve Chinese Subjects With Fabry Disease
Brief Summary: The main aim of the study is to assess the safety of REPLAGAL.
Study participants will receive REPLAGAL as an intravenous infusion every other week for 52 weeks.
Participants will visit their study clinic many times throughout the study.